Patents by Inventor Ving G. Lee

Ving G. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ROR1 MACROCYCLIC PEPTIDES AND COMPOSITIONS
    Publication number: 20240116988
    Abstract: There are disclosed novel anti-ROR1 macrocyclic peptides and their conjugates with general structure of formula (I), which can be used as ROR1 inhibitors.
    Type: Application
    Filed: August 23, 2023
    Publication date: April 11, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: JENNIFER X. QIAO, VING G. LEE, TAMMY C. WANG, MICHAEL A. POSS
  • N-terminally modified GLP-1 receptor modulators
    Patent number: 7960349
    Abstract: The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that may stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: June 14, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: William R. Ewing, Claudio Mapelli, Douglas James Riexinger, Ving G. Lee, Richard B. Sulsky, Yeheng Zhu
  • Sustained release glp-1 receptor modulators
    Publication number: 20100022457
    Abstract: The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.
    Type: Application
    Filed: November 8, 2006
    Publication date: January 28, 2010
    Inventors: Feng Qian, William R. Ewing, Claudio Mapelli, Douglas James Riexinger, Ving G. Lee, Richard B. Sulsky, Yeheng Zhu, Tasir Shamsul Haque, Rogelio L. Martinez, Vijay Naringrekar, Nina Ni, Lori S. Burton
  • Sustained release GLP-1 receptor modulators
    Patent number: 7534763
    Abstract: The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: May 19, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Feng Qian, William R. Ewing, Claudio Mapelli, Douglas James Riexinger, Ving G. Lee, Richard B. Sulsky, Yeheng Zhu, Tasir Shamsul Haque, Rogelio L. Martinez, Vijay Naringrekar, Nina Ni, Lori S. Burton
  • HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
    Publication number: 20080242593
    Abstract: The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
    Type: Application
    Filed: March 3, 2008
    Publication date: October 2, 2008
    Inventors: William R. Ewing, Claudio Mapelli, Richard B. Sulsky, Tasir Shamsul Haque, Ving G. Lee, Douglas James Riexinger, Rogelio L. Martinez, Yeheng Zhu
  • Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions
    Patent number: 7417028
    Abstract: The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: August 26, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: William R. Ewing, Claudio Mapelli, Richard B. Sulsky, Tasir Shamsul Haque, Ving G. Lee, Douglas James Riexinger, Rogelio L. Martinez, Yeheng Zhu
  • ACE-diuretics
    Patent number: 4888424
    Abstract: Hypotensive activity is exhibited by compounds having the formulas ##STR1##
    Type: Grant
    Filed: February 27, 1984
    Date of Patent: December 19, 1989
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Joseph E. Sundeen, David Floyd, Ving G. Lee